AnaptysBio/ANAB

$19.87

0.2%
-
1D1W1MYTD1YMAX

About AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Ticker

ANAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Faga

Employees

117

Headquarters

San diego, United States

AnaptysBio Metrics

BasicAdvanced
$574.6M
Market cap
-
P/E ratio
-$6.07
EPS
-0.27
Beta
-
Dividend rate
$574.6M
-0.27061
$27.50
$13.36
325.29K
10.866
-30.79%
-93.44%
-32.75%
33.491
6.481
6.522
66.78%
-32.73%
-38.84%

What the Analysts think about AnaptysBio

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
127.58% upside
High $80.00
Low $20.00
$19.87
Current price
$45.22
Average price target

AnaptysBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-468.88% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$9M
172.73%
Net income
$-42.2M
13.14%
Profit margin
-468.88%
-58.52%

AnaptysBio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.58
-$1.50
-$1.41
-$1.59
-
Expected
-$1.05
-$1.70
-$1.79
-$1.60
-$1.57
Surprise
50.76%
-11.63%
-21.4%
-0.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AnaptysBio stock?

AnaptysBio (ANAB) has a market cap of $530.71M as of April 21, 2024.

What is the P/E ratio for AnaptysBio stock?

The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of April 21, 2024.

Does AnaptysBio stock pay dividends?

No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next AnaptysBio dividend payment date?

AnaptysBio (ANAB) stock does not pay dividends to its shareholders.

What is the beta indicator for AnaptysBio?

AnaptysBio (ANAB) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.

What is the AnaptysBio stock price target?

The target price for AnaptysBio (ANAB) stock is $45.22, which is 127.58% above the current price of $19.87. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AnaptysBio stock

Buy or sell AnaptysBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing